INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2022

Disclosure of detailed information about intangible assets [abstract]

INTANGIBLE ASSETS

8 INTANGIBLE ASSETS

	2021		2022
	S$		S$
Goodwill		355		355
Intellectual properties licenses (Note (a))		22,827		12,127
Computer software licenses (Note (b))		8,841		6,327
Total		32,023		18,809

(a) Intellectual properties licenses

	2021		2022
	S$		S$
Cost:
At beginning of financial year		62,060		62,060
Additions		-		-
At end of financial year		62,060		62,060
Accumulated amortization:
At beginning of financial year		28,533		39,233
Amortization charge		10,700		10,700
At end of financial year		39,233		49,933
Carrying value		22,827		12,127

CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2020, 2021 and 2022

(b) Computer software licenses

	2021			2022
	S$			S$
Cost:
At beginning of financial year		11,873			11,855
Additions		-			-
Currency realignment		(18	)		(61	)
At end of financial year		11,855			11,794
Accumulated amortization:
At beginning of financial year		507			3,014
Amortization charge		2,512			2,500
Currency realignment		(5	)		(47	)
At end of financial year		3,014			5,467
Carrying value		8,841			6,327

(c) Amortization expense is analyzed as followed:

Intellectual properties licenses	10,700		10,700
Computer software licenses	2,512		2,500
Total	13,212		13,200
Less: Accounted under
“Research and development expenses” (Note 17)	(10,700	)	(10,700	)
	2,512		2,500

Management has evaluated, assessed and concluded that there is no indication of impairment for the intangible assets and accordingly no impairment allowance is necessary.